On Jul. 13, 2021, RELIEF THERAPEUTICS reported that its collaboration partner, NRx Pharmaceuticals, and Quantum Leap Healthcare Collaborativeﾙ announced that they had begun treating patients with inhaled aviptadil in the I-SPY COVID Trial (NCT04488081), a phase 2 adaptive platform trial aimed at improving treatment for severely and critically ill COVID-19 patients.